Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Tesser

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Arthritis|May 17, 2018
Biosimilars Have Arrived: RituximabMaria Greenwald, John Tesser, K Lea Sewell
Arthritis Care & Research|January 31, 2018
Ethnographic Observational Study of the Biologic Initiation Conversation Between Rheumatologists and Biologic-Naive Rheumatoid Arthritis PatientsNicholas Kottak, John Tesser, Evan Leibowitz, et al.
Arthritis Research & Therapy|August 21, 2019
Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of ageJohn Tesser, Shelly Kafka, Raphael J DeHoratius, et al.
Arthritis Research & Therapy|November 3, 2023
Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trialsJohn Tesser, Ahmet Gül, Ewa Olech, et al.
The Journal of Rheumatology|April 17, 2004
Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritisJohn Tesser, Roy Fleischmann, Robin Dore, et al.
Clinical Rheumatology|March 21, 2022
Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registryJohn Tesser, Iris Lin, Natalie J Shiff, et al.
Arthritis and Rheumatism|June 10, 2004
The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditionsMichael H Schiff, Gino DiVittorio, John Tesser, et al.
Rheumatology and Therapy|November 14, 2025
Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United StatesChristina Charles-Schoeman, Patrick Zueger, Erin McDearmon-Blondell, et al.
Clinical Rheumatology|February 13, 2020
Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritisJeffrey Kaine, John Tesser, Liza Takiya, et al.
The Journal of Rheumatology|April 15, 2024
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)Gerd R Burmester, Filip Van den Bosch, John Tesser, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Arthritis|May 17, 2018
Biosimilars Have Arrived: RituximabMaria Greenwald, John Tesser, K Lea Sewell
Arthritis Care & Research|January 31, 2018
Ethnographic Observational Study of the Biologic Initiation Conversation Between Rheumatologists and Biologic-Naive Rheumatoid Arthritis PatientsNicholas Kottak, John Tesser, Evan Leibowitz, et al.
Arthritis Research & Therapy|August 21, 2019
Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of ageJohn Tesser, Shelly Kafka, Raphael J DeHoratius, et al.
Arthritis Research & Therapy|November 3, 2023
Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trialsJohn Tesser, Ahmet Gül, Ewa Olech, et al.
The Journal of Rheumatology|April 17, 2004
Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritisJohn Tesser, Roy Fleischmann, Robin Dore, et al.
Clinical Rheumatology|March 21, 2022
Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registryJohn Tesser, Iris Lin, Natalie J Shiff, et al.
Arthritis and Rheumatism|June 10, 2004
The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditionsMichael H Schiff, Gino DiVittorio, John Tesser, et al.
Rheumatology and Therapy|November 14, 2025
Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United StatesChristina Charles-Schoeman, Patrick Zueger, Erin McDearmon-Blondell, et al.
Clinical Rheumatology|February 13, 2020
Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritisJeffrey Kaine, John Tesser, Liza Takiya, et al.
The Journal of Rheumatology|April 15, 2024
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)Gerd R Burmester, Filip Van den Bosch, John Tesser, et al.
Pageof 2